Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction

American Journal of Cardiology

Volumn 115, Issue 7, 2015, Pages 986-991

  Yuyun, Matthew F ^a   Narayan, Hafid K ^a,b   Ng, Leong L ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; MIDREGIONAL PROADRENOMEDULLIN; PROADRENOMEDULLIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; HEART FAILURE; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; COMPLICATION; ELECTROCARDIOGRAPHY; HEALTH; HEART INFARCTION; METABOLISM; MORTALITY; SURVIVAL RATE; TRENDS;

ADRENOMEDULLIN; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; GLOBAL HEALTH; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 84922948751     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.01.027     Document Type: Review

References (40)

1. 1 Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., Eto, T., Adrenomedullin: a novel hypotensive peptide isolated from human pheochromacytoma. Biochem Biophys Res Commun 192 (1993), 553–560.
2. 2 Ishimitsu, T., Ono, H., Minami, J., Matsuoka, H., Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 111 (2006), 909–927.
3. 3 Pio, R., Martinez, A., Unsworth, E.J., Kowalak, J.A., Bengoechea, J.A., Zipfel, P.F., Elsasser, T.H., Cuttitta, F., Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 276 (2001), 12292–12300.
4. 4 Struck, J., Tao, C., Morgenthaler, N.G., Bergmann, A., Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 25 (2004), 1369–1372.
5. 5 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
6. 6 Pousset, F., Masson, F., Chavirovskaia, O., Isnard, R., Carayon, A., Golmard, J.L., Lechat, P., Thomas, D., Komajda, M., Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 21 (2000), 1009–1014.
7. 7 Richards, A.M., Doughty, R., Nicholls, M.G., MacMahon, S., Sharpe, N., Murphy, J., Espiner, E.A., Frampton, C., Yandle, T.G., Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol, 37, 2001, 183A.
8. 8 Gegenhuber, A., Struck, J., Dieplinger, B., Poelz, W., Pacher, R., Morgenthaler, N.G., Bergmann, A., Haltmayer, M., Mueller, T., Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13 (2007), 42–49.
9. 9 Adlbrecht, C., Huelsmann, M., Strunk, G., Berger, R., Moertl, D., Struck, J., Morgenthaler, N.G., Bergmann, A., Jakowitsch, J., Maurer, G., Lang, I.M., Pacher, R., Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11 (2009), 361–366.
10. 10 Potocki, M., Breidthardt, T., Reichlin, T., Morgenthaler, N.G., Bergmann, A., Noveanu, M., Schaub, N., Uthoff, H., Freidank, H., Buser, L., Bingisser, R., Christ, M., Mebazaa, A., Mueller, C., Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care, 13, 2009, R122.
11. 11 Masson, S., Latini, R., Carbonieri, E., Moretti, L., Rossi, M.G., Ciricugno, S., Milani, V., Marchioli, R., Struck, J., Bergmann, A., Maggioni, A.P., Tognoni, G., Tavazzi, L., Investigators G-H. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 12 (2010), 338–347.
12. 12 Neuhold, S., Huelsmann, M., Strunk, G., Struck, J., Adlbrecht, C., Gouya, G., Elhenicky, M., Pacher, R., Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 56 (2010), 121–126.
13. 13 von Haehling, S., Filippatos, G.S., Papassotiriou, J., Cicoira, M., Jankowska, E.A., Doehner, W., Rozentryt, P., Vassanelli, C., Struck, J., Banasiak, W., Ponikowski, P., Kremastinos, D., Bergmann, A., Morgenthaler, N.G., Anker, S.D., Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12 (2010), 484–491.
14. 14 Maisel, A., Mueller, C., Nowak, R.M., Peacock, W.F., Ponikowski, P., Mockel, M., Hogan, C., Wu, A.H., Richards, M., Clopton, P., Filippatos, G.S., Di Somma, S., Anand, I., Ng, L.L., Daniels, L.B., Neath, S.X., Christenson, R., Potocki, M., McCord, J., Hartmann, O., Morgenthaler, N.G., Anker, S.D., Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 58 (2011), 1057–1067.
15. 15 Shah, R.V., Truong, Q.A., Gaggin, H.K., Pfannkuche, J., Hartmann, O., Januzzi, J.L. Jr., Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J, 33, 2012, 2197.
16. 16 Cinar, O., Cevik, E., Acar, A., Kaya, C., Ardic, S., Comert, B., Yokusoglu, M., Bilgi, C., Meisner, M., Madsen, T., Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients. Am J Emerg Med 30 (2012), 1915–1920.
17. 17 Bosselmann, H., Egstrup, M., Rossing, K., Gustafsson, I., Gustafsson, F., Tonder, N., Kistorp, C.N., Goetze, J.P., Schou, M., Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int J Cardiol 170 (2013), 202–207.
18. 18 Xue, Y., Taub, P., Iqbal, N., Fard, A., Clopton, P., Maisel, A., Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. Eur J Heart Fail 15 (2013), 1343–1349.
19. 19 Travaglino, F., Russo, V., De Berardinis, B., Numeroso, F., Catania, P., Cervellin, G., Nigra, S.G., Geraci, F., Bressan, M.A., Guerrini, S., Cavazza, M., Folli, C., Monzani, V., Battista, S., Mengozzi, G., Noto, P., Carpinteri, G., Semplicini, A., Stella, F., Ingrassia, S., Moscatelli, P., Giuntini, P., Salerno, G., Cardelli, P., Di Somma, S., Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med 32 (2014), 334–341.
20. 20 Khan, S.Q., O'Brien, R.J., Struck, J., Quinn, P., Morgenthaler, N., Squire, I., Davies, J., Bergmann, A., Ng, L.L., Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49 (2007), 1525–1532.
21. 21 Behnes, M., Papassotiriou, J., Walter, T., Fiedler, E., Sauer, T., Lang, S., Elmas, E., Hoffmann, U., Borggrefel, M., Brueckmann, M., Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med 46 (2008), 204–211.
22. 22 Dhillon, O.S., Khan, S.Q., Narayan, H.K., Ng, K.H., Struck, J., Quinn, P.A., Morgenthaler, N.G., Squire, I.B., Davies, J.E., Bergmann, A., Ng, L.L., Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 56 (2010), 125–133.
23. 23 Walter, T., Brueckmann, M., Lang, S., Sauer, T., Fiedler, E., Papassotirou, J., Behnes, M., Elmas, E., Borggrefe, M., Bertsch, T., Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction. Clin Lab 56 (2010), 303–309.
24. 24 Klip, I.T., Voors, A.A., Anker, S.D., Hillege, H.L., Struck, J., Squire, I., van Veldhuisen, D.J., Dickstein, K., investigators O. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 97 (2011), 892–898.
25. 25 Dzielinska, Z., Malek, L.A., Januszewicz, A., Prejbisz, A., Pregowski, J., Tyczynski, P., Makowiecka-Ciesla, M., Janas, J., Demkow, M., Ruzyllo, W., Adrenomedullin concentrations at two time points following myocardial infarction and prediction of mid-term outcomes. Arch Med Sci 7 (2011), 971–976.
26. 26 Wild, P.S., Schnabel, R.B., Lubos, E., Zeller, T., Sinning, C.R., Keller, T., Tzikas, S., Lackner, K.J., Peetz, D., Rupprecht, H.J., Bickel, C., Morgenthaler, N.G., Papassotiriou, J., Tiret, L., Munzel, T., Blankenberg, S., Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem 58 (2012), 226–236.
27. 27 Meune, C., Balmelli, C., Twerenbold, R., Reiter, M., Reichlin, T., Ziller, R., Drexler, B., Stelzig, C., Freese, M., Wolf, C., Haaf, P., Osswald, S., Mueller, C., Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin. Int J Cardiol 167 (2013), 1164–1169.
28. 28 Tzikas, S., Keller, T., Ojeda, F.M., Zeller, T., Wild, P.S., Lubos, E., Kunde, J., Baldus, S., Bickel, C., Lackner, K.J., Munzel, T.F., Blankenberg, S., MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart 99 (2013), 388–395.
29. 29 Richards, A.M., Nicholls, M.G., Yandle, T.G., Frampton, C., Espiner, E.A., Turner, J.G., Buttimore, R.C., Lainchbury, J.G., Elliott, J.M., Ikram, H., Crozier, I.G., Smyth, D.W., Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998), 1921–1929.
30. 30 Nagaya, N., Nishikimi, T., Uematsu, M., Yoshitomi, Y., Miyao, Y., Miyazaki, S., Goto, Y., Kojima, S., Kuramochi, M., Matsuo, H., Kangawa, K., Nonogi, H., Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 81 (1999), 483–487.
31. 31 Katayama, T., Nakashima, H., Honda, Y., Suzuki, S., Yano, K., Relationship between adrenomedullin and left-ventricular systolic function and mortality in acute myocardial infarction. Angiology 56 (2005), 35–42.
32. 32 Haaf, P., Twerenbold, R., Reichlin, T., Faoro, J., Reiter, M., Meune, C., Steuer, S., Bassetti, S., Ziller, R., Balmelli, C., Campodarve, I., Zellweger, C., Kilchenmann, A., Irfan, A., Papassotiriou, J., Drexler, B., Mueller, C., Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. Int J Cardiol 168 (2013), 1048–1055.
33. 33 Xue, Y., Taub, P., Fard, A., Iqbal, N.M., Nguyen, H., Clopton, P., Maisel, A.S., Elevated mid-region pro-adrenomedullin is associated with increased mortality in stable outpatients with diastolic dysfunction. Eur Heart J 32 (2011), 907–908.
34. 34 Alehagen, U., Dahlstrom, U., Rehfeld, J.F., Goetze, J.P., Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. J Card Fail 19 (2013), 31–39.
35. 35 Schnabel, R.B., Schulz, A., Messow, C.M., Lubos, E., Wild, P.S., Zeller, T., Sinning, C.R., Rupprecht, H.J., Bickel, C., Peetz, D., Cambien, F., Kempf, T., Wollert, K.C., Benjamin, E.J., Lackner, K.J., Munzel, T.F., Tiret, L., Vasan, R.S., Blankenberg, S., Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 31 (2010), 3024–3031.
36. 36 Sabatine, M.S., Morrow, D.A., de Lemos, J.A., Omland, T., Sloan, S., Jarolim, P., Solomon, S.D., Pfeffer, M.A., Braunwald, E., Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 125 (2012), 233–240.
37. 37 Nishida, H., Horio, T., Suzuki, Y., Iwashima, Y., Kamide, K., Kangawa, K., Kawano, Y., Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 29 (2008), 599–605.
38. 38 Kato, J., Tsuruda, T., Kita, T., Kitamura, K., Eto, T., Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25 (2005), 2480–2487.
39. 39 Melander, O., Newton-Cheh, C., Almgren, P., Hedblad, B., Berglund, G., Engstrom, G., Persson, M., Smith, J.G., Magnusson, M., Christensson, A., Struck, J., Morgenthaler, N.G., Bergmann, A., Pencina, M.J., Wang, T.J., Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302 (2009), 49–57.
40. 40 McLatchie, L.M., Fraser, N.J., Main, M.J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M.G., Foord, S.M., RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998), 333–339.